GlassScriptPhysician profile
Robin Y Rye
NPI 1639134059
$10,911.69
in general payments reported to CMS, 2019-2025
44 companies · $2,443 in 2025
The $2,443 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,306 · 2022: $2,178 · 2023: $1,896 · 2024: $2,089 · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,166 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,166.41 |
| Education | $261.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,762.55 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,268.75 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $1,059.65 | 2021-2025 | |
| Abbvie INC. | $1,051.78 | 2021-2025 | |
| Amgen INC. | $653.91 | 2021-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $598.86 | 2021-2025 | Veozah, Myrbetriq |
| Bausch Health US, LLC | $553.33 | 2021-2025 | Aplenzin, Wellbutrin |
| Lilly USA, LLC | $549.99 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Horizon Therapeutics Plc | $336.58 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $328.48 | 2021-2024 | |
| Esperion Therapeutics, INC. | $313.86 | 2021-2023 | Nexletol |
| Phathom Pharmaceuticals, INC. | $281.51 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $250.00 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $224.32 | 2021-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $219.07 | 2021-2025 | Trintellix |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $125.00 | 2022 | |
| Ardelyx, INC. | $111.60 | 2024-2025 | Ibsrela |
| Amarin Pharma, INC. | $104.53 | 2021-2022 | |
| Revance Therapeutics, INC. | $97.11 | 2025 | Daxxify |
| Pfizer INC. | $95.34 | 2023-2025 | |
| Glaxosmithkline, LLC. | $92.97 | 2021-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.70 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $77.21 | 2024 | Cologuard Collection Kit |
| Merz North America, INC. | $72.30 | 2023 | Xeomin |
| Abbott Laboratories | $70.85 | 2022-2024 | Freestyle Libre 3 |
| Averitas Pharma INC. | $64.99 | 2024 | Qutenza |
| Axsome Therapeutics, INC. | $57.18 | 2025 | Symbravo, Auvelity |
| Merck Sharp & Dohme LLC | $54.39 | 2021-2023 | Belsomra |
| Azurity Pharmaceuticals, INC. | $38.27 | 2023-2025 | Edarbyclor, Alvesco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.74 | 2021 | |
| Tris Pharma INC | $36.61 | 2024 | Dyanavel Xr |
| Corium, LLC | $31.29 | 2023-2025 | Azstarys, Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $29.48 | 2022 | |
| Insulet Corporation | $22.38 | 2023 | Omnipod |
| Endo USA, INC. | $21.76 | 2025 | Aveed, Xiaflex |
| Viatris Specialty LLC | $18.20 | 2025 | Yupelri |
| Supernus Pharmaceuticals, INC. | $17.48 | 2024 | Qelbree |
| Sunovion Pharmaceuticals INC. | $15.36 | 2021 | |
| Exeltis, USA INC. | $14.71 | 2024 | Slynd |
| Nabriva Therapeutics, Plc | $13.74 | 2021 | |
| Intra-Sana Laboratories | $13.65 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Forte Bio-Pharma LLC | $12.94 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.85 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Rye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.